The Story Behind MIDBA: An Exclusive Interview - Ypsomed

A recent regulatory milestone is changing how pharmaceutical companies approach device transitions during clinical development. The European Medicines Agency’s qualification of the Molecule Independent Device Bridging Approach (MIDBA) introduces a new framework that may reduce or eliminate the need for certain molecule-specific pharmacokinetic (PK) bridging studies when moving from prefilled syringes to autoinjectors.

By leveraging existing comparability data, MIDBA has the potential to streamline development programs, reduce costs, and accelerate timelines while maintaining confidence in drug delivery performance. The framework also provides greater regulatory clarity for sponsors seeking to introduce patient-friendly delivery devices without repeating resource-intensive clinical studies. Experts discuss the scientific rationale behind the qualification, the requirements for applying the approach to different device platforms, and its broader implications for future drug-device combination products.

As regulatory agencies continue to explore innovative development pathways, this precedent may help shape more efficient global strategies for biologics and combination product development.